Nye endokrine behandlinger forlænger overlevelsen ved kastrationsresistent prostatacancer

Klaus Brasso; Frederik Birkebæk Thomsen; Kasper Drimer Berg; Martin Andreas Røder; Peter Iversen

Nye endokrine behandlinger forlænger overlevelsen ved kastrationsresistent prostatacancer

Translated title of the contribution: New endocrine treatments prolong survival of patients with castration-resistant prostate cancer.

Klaus Brasso, Frederik Birkebæk Thomsen, Kasper Drimer Berg, Martin Andreas Røder, Peter Iversen

Abstract

Prostate cancer that progresses despite castrate levels of serum testosterone is defined as castration-resistant prostate cancer (CRPC). Molecular investigations of the disease have established that progression of CRPC remains driven by androgen receptor signalling and that CRPC continues to respond to hormonal manipulation. Recently, new endocrine treatments including an androgen receptor signalling inhibitor and a testosterone synthesis inhibitor have been approved for treatment of CRPC. We review the pivotal phase 3 trials and discuss their implications for future treatment of CRPC.

Translated title of the contribution	New endocrine treatments prolong survival of patients with castration-resistant prostate cancer.
Original language	Danish
Journal	Ugeskrift for Laeger
Volume	175
Issue number	40
Pages (from-to)	2328-2332
Number of pages	5
ISSN	0041-5782
Publication status	Published - 30 Sep 2013

Cite this

@article{ae1e0f988a1d4bb0b7976ff45cc41e22,

title = "Nye endokrine behandlinger forl{\ae}nger overlevelsen ved kastrationsresistent prostatacancer",

abstract = "Prostate cancer that progresses despite castrate levels of serum testosterone is defined as castration-resistant prostate cancer (CRPC). Molecular investigations of the disease have established that progression of CRPC remains driven by androgen receptor signalling and that CRPC continues to respond to hormonal manipulation. Recently, new endocrine treatments including an androgen receptor signalling inhibitor and a testosterone synthesis inhibitor have been approved for treatment of CRPC. We review the pivotal phase 3 trials and discuss their implications for future treatment of CRPC.",

author = "Klaus Brasso and Thomsen, {Frederik Birkeb{\ae}k} and Berg, {Kasper Drimer} and R{\o}der, {Martin Andreas} and Peter Iversen",

year = "2013",

month = sep,

day = "30",

language = "Dansk",

volume = "175",

pages = "2328--2332",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "40",

}

TY - JOUR

T1 - Nye endokrine behandlinger forlænger overlevelsen ved kastrationsresistent prostatacancer

AU - Brasso, Klaus

AU - Thomsen, Frederik Birkebæk

AU - Berg, Kasper Drimer

AU - Røder, Martin Andreas

AU - Iversen, Peter

PY - 2013/9/30

Y1 - 2013/9/30

N2 - Prostate cancer that progresses despite castrate levels of serum testosterone is defined as castration-resistant prostate cancer (CRPC). Molecular investigations of the disease have established that progression of CRPC remains driven by androgen receptor signalling and that CRPC continues to respond to hormonal manipulation. Recently, new endocrine treatments including an androgen receptor signalling inhibitor and a testosterone synthesis inhibitor have been approved for treatment of CRPC. We review the pivotal phase 3 trials and discuss their implications for future treatment of CRPC.

AB - Prostate cancer that progresses despite castrate levels of serum testosterone is defined as castration-resistant prostate cancer (CRPC). Molecular investigations of the disease have established that progression of CRPC remains driven by androgen receptor signalling and that CRPC continues to respond to hormonal manipulation. Recently, new endocrine treatments including an androgen receptor signalling inhibitor and a testosterone synthesis inhibitor have been approved for treatment of CRPC. We review the pivotal phase 3 trials and discuss their implications for future treatment of CRPC.

M3 - Tidsskriftartikel

C2 - 24079321

VL - 175

SP - 2328

EP - 2332

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 40

ER -

Nye endokrine behandlinger forlænger overlevelsen ved kastrationsresistent prostatacancer

Abstract

Fingerprint

Cite this